星空体育官方入口网站网址大全-登录入口官网

#利妥昔#

179篇内容 | 2272人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660540, encodeId=bc531660540ac, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Rheumatology：复发性或难治性SLE缓解诱导后的利妥昔单抗维持治疗, objectType=article, longId=736513, objectId=a3e7e36513f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3e7e36513f0, replyNumber=0, likeNumber=80, createdTime=2023-01-16, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3e7e36513f0, moduleTitle=Rheumatology：复发性或难治性SLE缓解诱导后的利妥昔单抗维持治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a3e7e36513f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660534, encodeId=a1621660534e9, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, objectType=article, longId=731945, objectId=fdbde3194517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdbde3194517, replyNumber=0, likeNumber=82, createdTime=2023-01-26, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdbde3194517, moduleTitle=Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fdbde3194517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660529, encodeId=33f0166052932, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=HAEMATOLOGICA：利妥昔单抗联合基于 LMB 的化疗方案治疗儿童和青少年原发性纵隔大 B 细胞淋巴瘤取得出色的生存率 , objectType=article, longId=300877, objectId=34583008e7c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34583008e7c5, replyNumber=0, likeNumber=78, createdTime=2023-01-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34583008e7c5, moduleTitle=HAEMATOLOGICA：利妥昔单抗联合基于 LMB 的化疗方案治疗儿童和青少年原发性纵隔大 B 细胞淋巴瘤取得出色的生存率 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=34583008e7c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660532, encodeId=6dcc1660532c7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=A&R：B细胞数预测接受利妥昔单抗治疗的患者接种SARS-CoV-2疫苗后的体液和细胞反应, objectType=article, longId=729080, objectId=64cee29080f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64cee29080f1, replyNumber=0, likeNumber=103, createdTime=2022-09-21, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64cee29080f1, moduleTitle=A&R：B细胞数预测接受利妥昔单抗治疗的患者接种SARS-CoV-2疫苗后的体液和细胞反应, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=64cee29080f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660530, encodeId=e53f16605306a, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=A&R：B细胞重建与接受利妥昔单抗治疗的风湿病患者的 COVID-19疫苗反应性密切相关, objectType=article, longId=726488, objectId=0d32e2648830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d32e2648830, replyNumber=0, likeNumber=73, createdTime=2022-08-20, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d32e2648830, moduleTitle=A&R：B细胞重建与接受利妥昔单抗治疗的风湿病患者的 COVID-19疫苗反应性密切相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0d32e2648830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660536, encodeId=56a31660536ed, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：利妥昔单抗联合来那度胺或化疗治疗滤泡性淋巴瘤的长期预后, objectType=article, longId=735726, objectId=b3d4e3572648, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d4e3572648, replyNumber=0, likeNumber=71, createdTime=2023-04-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d4e3572648, moduleTitle=J Clin Oncol：利妥昔单抗联合来那度胺或化疗治疗滤泡性淋巴瘤的长期预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b3d4e3572648)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660527, encodeId=06b4166052ec1, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=AJH：单剂量与低剂量利妥昔单抗治疗皮质类固醇耐药或复发性 ITP：一项多中心、随机、对照研究, objectType=article, longId=295312, objectId=76172953129d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76172953129d, replyNumber=0, likeNumber=77, createdTime=2022-07-02, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76172953129d, moduleTitle=AJH：单剂量与低剂量利妥昔单抗治疗皮质类固醇耐药或复发性 ITP：一项多中心、随机、对照研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=76172953129d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660531, encodeId=d6141660531b0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=A&R：利妥昔单抗会损害B细胞反应，但不会损害T细胞对自身免疫性疾病中COVID-19疫苗的反应, objectType=article, longId=729002, objectId=a298e29002b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a298e29002b7, replyNumber=0, likeNumber=88, createdTime=2023-03-12, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a298e29002b7, moduleTitle=A&R：利妥昔单抗会损害B细胞反应，但不会损害T细胞对自身免疫性疾病中COVID-19疫苗的反应, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a298e29002b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660538, encodeId=56a01660538a4, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Rheumatology：低剂量利妥昔单抗对难治性特发性炎性肌病有效, objectType=article, longId=735901, objectId=367be3590160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367be3590160, replyNumber=0, likeNumber=64, createdTime=2023-01-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367be3590160, moduleTitle=Rheumatology：低剂量利妥昔单抗对难治性特发性炎性肌病有效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=367be3590160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660539, encodeId=70f216605393d, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JNNP：利妥昔单抗治疗多发性硬化症期间母乳喂养的安全性, objectType=article, longId=736162, objectId=46eae3616226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46eae3616226, replyNumber=0, likeNumber=125, createdTime=2022-11-26, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46eae3616226, moduleTitle=JNNP：利妥昔单抗治疗多发性硬化症期间母乳喂养的安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46eae3616226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660513, encodeId=3148166051353, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol ：利妥昔单抗+环磷酰胺+贝利木单抗治疗狼疮性肾炎的II期随机试验, objectType=article, longId=217611, objectId=3cf021e611ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf021e611ba, replyNumber=0, likeNumber=0, createdTime=2021-10-21, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf021e611ba, moduleTitle=Arthritis Rheumatol ：利妥昔单抗+环磷酰胺+贝利木单抗治疗狼疮性肾炎的II期随机试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3cf021e611ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660537, encodeId=2659166053e2e, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤, objectType=article, longId=735739, objectId=d3ece357396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3ece357396e, replyNumber=0, likeNumber=74, createdTime=2023-06-29, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3ece357396e, moduleTitle=J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d3ece357396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660535, encodeId=cf54166053559, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=【Blood Adv】利妥昔单抗时代低级别B细胞淋巴瘤的死亡原因分析-来自一项前瞻性队列研究, objectType=article, longId=734612, objectId=dddce3461202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dddce3461202, replyNumber=0, likeNumber=61, createdTime=2023-02-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dddce3461202, moduleTitle=【Blood Adv】利妥昔单抗时代低级别B细胞淋巴瘤的死亡原因分析-来自一项前瞻性队列研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dddce3461202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660516, encodeId=2b9d166051625, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Frontiers in Immunology: IL-40：一种新的B细胞相关细胞因子在利妥昔单抗治疗类风湿性关节炎后上调减少，并与疾病活性、自身抗体和NETosis相关, objectType=article, longId=220020, objectId=587a22002088, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=587a22002088, replyNumber=0, likeNumber=72, createdTime=2022-09-04, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=587a22002088, moduleTitle=Frontiers in Immunology: IL-40：一种新的B细胞相关细胞因子在利妥昔单抗治疗类风湿性关节炎后上调减少，并与疾病活性、自身抗体和NETosis相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=587a22002088)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660505, encodeId=d70b166050523, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JCEM：利妥昔单抗靶向治疗在活动性中度至重度Graves眼病患者的疗效, objectType=article, longId=216674, objectId=c00c2166e4fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c00c2166e4fb, replyNumber=0, likeNumber=79, createdTime=2021-12-25, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c00c2166e4fb, moduleTitle=JCEM：利妥昔单抗靶向治疗在活动性中度至重度Graves眼病患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c00c2166e4fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660519, encodeId=84371660519a0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：黄晓军团队发现全反式维甲酸+低剂量利妥昔单抗治疗难治/复发性免疫性血小板减少症, objectType=article, longId=220605, objectId=a14b22060538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a14b22060538, replyNumber=0, likeNumber=76, createdTime=2022-05-21, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a14b22060538, moduleTitle=Blood：黄晓军团队发现全反式维甲酸+低剂量利妥昔单抗治疗难治/复发性免疫性血小板减少症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a14b22060538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660512, encodeId=415416605128d, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Rheumatology：尿蛋白可以预测活动性狼疮性肾炎和利妥昔单抗治疗的反应, objectType=article, longId=217608, objectId=a55121e60808, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a55121e60808, replyNumber=0, likeNumber=62, createdTime=2022-09-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a55121e60808, moduleTitle=Rheumatology：尿蛋白可以预测活动性狼疮性肾炎和利妥昔单抗治疗的反应, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a55121e60808)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660533, encodeId=c510166053380, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=利妥昔单抗治疗结缔组织病相关间质性肺病对肺功能的影响, objectType=article, longId=730269, objectId=6d84e3026909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d84e3026909, replyNumber=0, likeNumber=67, createdTime=2022-12-10, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d84e3026909, moduleTitle=利妥昔单抗治疗结缔组织病相关间质性肺病对肺功能的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6d84e3026909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660521, encodeId=7d1e1660521ad, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JCEM:利妥昔单抗辅助治疗在青年Graves病中的探索性试验, objectType=article, longId=221217, objectId=daf222121ee2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daf222121ee2, replyNumber=0, likeNumber=74, createdTime=2022-07-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daf222121ee2, moduleTitle=JCEM:利妥昔单抗辅助治疗在青年Graves病中的探索性试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=daf222121ee2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660520, encodeId=9714166052029, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, objectType=article, longId=221135, objectId=393f22113570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=393f22113570, replyNumber=0, likeNumber=0, createdTime=2022-07-31, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393f22113570, moduleTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=393f22113570)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Rheumatology：复发性或难治性SLE缓解诱导后的利妥昔单抗维持治疗

2023-01-16

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

2023-01-26

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

HAEMATOLOGICA：利妥昔单抗联合基于 LMB 的化疗方案治疗儿童和青少年原发性纵隔大 B 细胞淋巴瘤取得出色的生存率

2023-01-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

A&R：B细胞数预测接受利妥昔单抗治疗的患者接种SARS-CoV-2疫苗后的体液和细胞反应

2022-09-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

A&R：B细胞重建与接受利妥昔单抗治疗的风湿病患者的 COVID-19疫苗反应性密切相关

2022-08-20

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：利妥昔单抗联合来那度胺或化疗治疗滤泡性淋巴瘤的长期预后

2023-04-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

AJH：单剂量与低剂量利妥昔单抗治疗皮质类固醇耐药或复发性 ITP：一项多中心、随机、对照研究

2022-07-02

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

A&R：利妥昔单抗会损害B细胞反应，但不会损害T细胞对自身免疫性疾病中COVID-19疫苗的反应

2023-03-12

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Rheumatology：低剂量利妥昔单抗对难治性特发性炎性肌病有效

2023-01-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JNNP：利妥昔单抗治疗多发性硬化症期间母乳喂养的安全性

2022-11-26

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol ：利妥昔单抗+环磷酰胺+贝利木单抗治疗狼疮性肾炎的II期随机试验

2021-10-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤

2023-06-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

【Blood Adv】利妥昔单抗时代低级别B细胞淋巴瘤的死亡原因分析-来自一项前瞻性队列研究

2023-02-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Frontiers in Immunology: IL-40：一种新的B细胞相关细胞因子在利妥昔单抗治疗类风湿性关节炎后上调减少，并与疾病活性、自身抗体和NETosis相关

2022-09-04

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JCEM：利妥昔单抗靶向治疗在活动性中度至重度Graves眼病患者的疗效

2021-12-25

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：黄晓军团队发现全反式维甲酸+低剂量利妥昔单抗治疗难治/复发性免疫性血小板减少症

2022-05-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Rheumatology：尿蛋白可以预测活动性狼疮性肾炎和利妥昔单抗治疗的反应

2022-09-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

利妥昔单抗治疗结缔组织病相关间质性肺病对肺功能的影响

2022-12-10

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JCEM:利妥昔单抗辅助治疗在青年Graves病中的探索性试验

2022-07-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效

2022-07-31

科室
- - 订阅+
  - 更多科室
工具
服务